The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Research shows that glucagon-like peptide-1 receptor agonists (or GLP-1s – think Ozempic or similar medications) are changing ...

UNITED LAB (03933.HK) announced that it had entered into an exclusive licensing agreement with its wholly-owned subsidiary ...

Researchers conducted a randomized clinical trial examining the effects of semaglutide in non-treatment-seeking adults with alcohol-use disorder.

New integration means streamlined ordering and paying experiences for patients, with the same direct shipping and the best self-pay price on single-dose Zepbound vialsNEW YORK CITY, March 24, 2025 ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

Novo Nordisk (NVO) secured exclusive global rights to United Laboratories International's therapeutic candidate for obesity and type 2 diabetes in a licensing deal worth up to $2 billion. The product ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Trainwreck star Amy Schumer revealed what 'red flags' she noticed while taking Ozempic while detailing the unfortunate side ...

Zerodha’s Nithin Kamath sparks debate on Ozempic, Mounjaro & their game-changing impact on obesity, addiction & industries. Is India ready for this shift?